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1. INTRODUCTION {#cas13648-sec-0001}
===============

Adoptive T‐cell therapy is a promising approach to cancer therapy.[1](#cas13648-bib-0001){ref-type="ref"} Tumor‐infiltrating lymphocyte infusion is a classic and effective method for treating melanoma patients.[2](#cas13648-bib-0002){ref-type="ref"}, [3](#cas13648-bib-0003){ref-type="ref"} Isolated tumor‐infiltrating lymphocytes (TILs) are restimulated by tumor‐associated antigen (TAA)‐loaded antigen‐presenting cells, and then expanded TILs are infused into patients. Gene transducing technologies have also recently been applied to adoptive T cell therapy. Artificially designed T‐cell receptor (TCR) or chimeric antigen receptor (CAR) against TAA and CAR target antigens are transduced into patients' T cells with TCR stimulation and expansion.[4](#cas13648-bib-0004){ref-type="ref"} As in TIL therapy, these transduced T cells are also re‐infused into patients to attack tumor cells. However, the therapeutic effects of tumor‐specific T cell transfer have been limited because infused T cells frequently lose functionality after transplantation.[1](#cas13648-bib-0001){ref-type="ref"}, [5](#cas13648-bib-0005){ref-type="ref"} The TAA‐specific T cells become exhausted and dysfunctional in the tumor microenvironment and through the T cell culture procedures.[6](#cas13648-bib-0006){ref-type="ref"}, [7](#cas13648-bib-0007){ref-type="ref"} Therefore, restoration and enforcement of T cell function and persistency could improve long‐term outcomes for cancer patients.

Memory T cells have been classified into two subpopulations: peripheral tissue‐homing effector memory T (T~EM~) cells and lymphatic tissue‐homing central memory T (T~CM~) cells.[8](#cas13648-bib-0008){ref-type="ref"} Novel memory T cell subpopulations, called stem cell memory T (T~SCM~) cells, were recently identified as the "stem" of memory T cells. Stem cell memory T cells expressed naïve T‐cell surface markers, CD44^low^CD62L^high^CCR7^+^ in mice and CD45RA^+^CD45RO^−^CCR7^+^CD62L^+^ in humans.[9](#cas13648-bib-0009){ref-type="ref"}, [10](#cas13648-bib-0010){ref-type="ref"} These cells possess high proliferative and long‐term survival abilities in vivo, producing a large number of effector T cells with potent antitumor functions.[11](#cas13648-bib-0011){ref-type="ref"}, [12](#cas13648-bib-0012){ref-type="ref"} Similar naïve‐like memory T cells were discovered in human and called memory T cells with a naive phenotype.[13](#cas13648-bib-0013){ref-type="ref"} A recent paper by Ahmed et al[14](#cas13648-bib-0014){ref-type="ref"} indicated that human T~SCM~ cells are highly proliferative but have long telomeres and high levels of telomerase activity.

Due to these superior features of T~SCM~ cells, methods of generating T~SCM~ cells in vitro for adoptive T cell therapy have been investigated. In 2009, Gattinoni et al[15](#cas13648-bib-0015){ref-type="ref"} first reported that a glycogen synthase kinase 3β inhibitor, TWS119, induces murine and human T~SCM~ cells by activating Wnt signals. TWS119 treatment arrested the cell cycle during TCR stimulation and inhibited the differentiation to T~CM~ and T~EM~ cells. Therefore, this method is only applicable for naïve T cells, and the number of induced T~SCM~ cells is limited. Alternative methods have been proposed by optimizing TCR strength, cytokine supplement (including interleukin \[IL\]‐7, IL‐15, and IL‐21), and drug treatment. These methods could generate T~SCM~ cells in vitro, but these methods still generate T~SCM~ cells from naïve T cells (Table [1](#cas13648-tbl-0001){ref-type="table"}).[16](#cas13648-bib-0016){ref-type="ref"}, [17](#cas13648-bib-0017){ref-type="ref"}, [18](#cas13648-bib-0018){ref-type="ref"}, [19](#cas13648-bib-0019){ref-type="ref"}, [20](#cas13648-bib-0020){ref-type="ref"} We have established a novel two‐step culture system for T~SCM~ induction, which is constituted by a "prime" step and an "induction" step, and have named the induced‐T~SCM~ "induced‐T~SCM~ (iT~SCM~)" cells.[12](#cas13648-bib-0012){ref-type="ref"} In this paper, we describe a detailed methodology of iT~SCM~ generation and report optimal conditions of priming and cytokine treatment. We also investigate the antitumor efficacy of human iT~SCM~ cells in a humanized mouse model.

###### 

Recently reported methods for stem cell memory T cell generation from naïve T cells

  Publication                                   Year   TCR procedure         TCR strength   Cytokine       Signaling inhibitor
  --------------------------------------------- ------ --------------------- -------------- -------------- ---------------------
  Gattinoni et al *Nat Med*                     2011   CD3/CD28 beads        Full           IL‐2           GSK3‐β (TWS119)
  Cieri et al *Blood*                           2013   CD3/CD28 beads        Full           IL‐7 + IL‐15   None
  Gomez‐Eerland et al *Hum Gene Ther Methods*   2014   CD3/CD28 beads        Full           IL‐7 + IL‐15   None
  Sabatino et al *Blood*                        2016   CD3/CD28 beads        Short (4 d)    IL‐7 + IL‐21   GSK3‐β (TWS119)
  Scholz et al *EBioMedicine*                   2016   CD3/CD28 beads        Full           IL‐2           mTOR (rapamycin)
  Alvarez‐Fernandez et al *J Trans Med*         2016   CD3/CD28 beads        Short (2 d)    IL‐21          None
  Hurton et al *Proc Natl Acad Sci USA*         2016   APC                   Full           mbIL‐15        None
  Kagoya et al *JCI Insight*                    2017   CD3/CD28 beads, APC   Short (1 d)    IL‐2 + IL‐15   None
  Jeza et al *Pan Afr Med J*                    2017   APC                   Full           IL‐21          mTOR (rapamycin)
  Zanon et al *Eur J Immunol*                   2017   CD3/CD28 beads, APC   Full           IL‐7 + IL‐15   None
  Kaartinen et al *Cytotherapy*                 2017   CD3/CD28 beads        Full           Low IL‐2       None

APC, antigen presenting cell; d, day; GSK3‐β, glycogen synthase kinase 3β; IL, interleukin; mb, membrane bound; TCR, T cell receptor.
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2. MATERIALS AND METHODS {#cas13648-sec-0002}
========================

2.1. OP9‐hDLL1 cell coculture {#cas13648-sec-0003}
-----------------------------

Human T cells were activated using the methods mentioned above. To activate Notch signaling, activated T cells were cocultured with OP9‐hDLL1 cells. Human T cells and OP9‐hDLL1 cells were cocultured with human IL‐2 (20 ng/mL; PeproTech), human IL‐7 (10 ng/mL; PeproTech), human IL‐15 (20 ng/mL; Biolegend), or human IL‐21 (20 ng/mL; PeproTech) in Minimum Essential Medium Eagle‐alpha modification for 11 days.

2.2. Statistics {#cas13648-sec-0004}
---------------

Statistical analysis was carried out using Student\'s *t*‐test, one‐way ANOVA and a long‐rank test, using GraphPad Prism version 6.05 software (GraphPad Software, La Jolla, CA, USA). The variance among the groups was estimated using the *F*‐test, and *P*‐values \<.05 were considered statistically significant. All data are presented as the mean ± SEM. Mice were randomly assigned to experimental groups. The investigators were not blinded to allocation during experiments and outcome assessment.

Further information regarding materials and methods is included in Tables [S1,S2](#cas13648-sup-0004){ref-type="supplementary-material"}.

3. RESULTS {#cas13648-sec-0005}
==========

3.1. Overview of iT~SCM~ cell generation {#cas13648-sec-0006}
----------------------------------------

Several methods for generating T~SCM~ have recently been reported. The strength of TCR stimulation, cytokine effects, and signaling inhibitors were associated with T~SCM~ generation from naïve T cells and are summarized in Table [1](#cas13648-tbl-0001){ref-type="table"}.[11](#cas13648-bib-0011){ref-type="ref"}, [16](#cas13648-bib-0016){ref-type="ref"}, [17](#cas13648-bib-0017){ref-type="ref"}, [18](#cas13648-bib-0018){ref-type="ref"}, [19](#cas13648-bib-0019){ref-type="ref"}, [20](#cas13648-bib-0020){ref-type="ref"}, [21](#cas13648-bib-0021){ref-type="ref"}, [22](#cas13648-bib-0022){ref-type="ref"}, [23](#cas13648-bib-0023){ref-type="ref"}, [24](#cas13648-bib-0024){ref-type="ref"}, [25](#cas13648-bib-0025){ref-type="ref"} In our two‐step culture system, T cells are first primed and expanded by strong TCR stimulation, and are then cocultured with OP9‐hDLL1 cells to convert into iT~SCM~ cells (Figure [1](#cas13648-fig-0001){ref-type="fig"}A). To acquire a large number of antigen‐specific CD8α^+^ T cells, we first isolated peripheral human CD8^+^ T cells, labeled with cell trace dye and co‐cultured them with autologous Epstein--Barr virus (EBV)‐transformed lymphoblastoid cell lines (LCLs) for 7 days in the "prime" step. Next, cell trace dye‐diluted activated T cells were purified by a cell sorter and were then transferred onto and cocultured with DLL1‐expressing OP9 stromal cells (OP9‐hDLL1) for 11 days in the "induction" step (Figure [1](#cas13648-fig-0001){ref-type="fig"}B). More than 90% of singlet live cells expressed CD8α and more than 80% of CD8α^+^ T cells highly proliferated (dividing more than six times) and mainly showed CD45RA^−^CCR7^−^ T~EM~ (76.4%) and CD45RA^−^CCR7^+^ T~CM~ (13.4%) phenotypes (Figure [2](#cas13648-fig-0002){ref-type="fig"}A). We then isolated phenotypical T~EM~ and T~CM~ cells and transferred them onto OP9‐hDLL1 layers with human IL‐7. Conversion efficiency from EBV‐specific activated human T cells to iT~SCM~ is 10% from T~EM~ cells and \>85% from T~CM~ cells (Figure [2](#cas13648-fig-0002){ref-type="fig"}B). In addition, the number of T~EM~‐derived CD8α^+^ T cells was not changed or was only slightly reduced, whereas that of T~CM~‐derived CD8α^+^ T cells was significantly increased (Figure [2](#cas13648-fig-0002){ref-type="fig"}C). To investigate the EBV‐specific recall response, we cocultured T~EM~, T~CM~, and iT~SCM~ cells with autologous LCL for 60 hours. The EBV‐specific iT~SCM~ cells recovered greater number of cells than the T~EM~ and T~CM~ cells did (Figure [2](#cas13648-fig-0002){ref-type="fig"}D). The same results could be acquired from several independent experiments using T cells from distinct healthy subjects. These data indicate that the coculture with OP9‐hDLL1 cells convert into iT~SCM~ from both T~EM~ and T~CM~ cells. However, the efficiency of iT~SCM~ generation from T~CM~ cells is higher than that from T~EM~ cells, and T~CM~ cells do proliferate during iT~SCM~ generation.

![Experimental outline for induced stem cell memory T (iT~SCM~) cell induction. A, Schematic for two‐step culture system for iT~SCM~ induction. Peripheral CD8α^+^ T cells are isolated and activated by T‐cell receptor stimulation for 7 d in the first step, called the prime step. Activated T cells are purified by cell sorting and transferred onto OP9‐hDLL1 cells for 11 d in the second step, the induction step. Evaluation of iT~SCM~ cells is carried out 11 d after OP9‐hDLL1 coculture. B, Detailed protocols for iT~SCM~ generation. Preparation of autologous lymphoblastoid cell lines (LCLs) and OP9‐hDLL1 feeder cells are necessary to induce human iT~SCM~ cells. Start with CD8α^+^ T cell isolation on Day −7 of the prime step (left). Peripheral CD8α^+^ T cells are negatively isolated from PBMCs and labeled by cell trace dye, followed by the addition of labeled‐CD8α^+^ T cells to irradiated autologous LCL and the start of coculture. Activated T cells, which are defined as cell trace dye‐diluted CD8α^+^ cells, are purified by cell sorting. Next, purified activated T cells (1 × 10^5 ^cells/mL) are cocultured with OP9‐hDLL1 cells in the presence of human interleukin‐7 (IL‐7; 10 ng/mL) (right). Harvesting CD8α^+^ T cells, adjusting cell density (1 × 10^5 ^cells/mL), and transferring onto a new OP9‐hDLL1 layer are carried out on Days 3 and 7. Coculture with OP9‐hDLL1 cells for 11 d induced iT~SCM~ cells, defined as CD8α^+^ CD45RA ^+^ C‐C chemokine receptor type 7 (CCR7)^+^ cells. Analysis earlier than Day 11 is possible, but the induction of iT~SCM~ cells was completed after more than 10 d of coculture. CFSE, carboxyfluorescein succinimidyl ester; CTFR, cell trace far red dye](CAS-109-2130-g001){#cas13648-fig-0001}

![Generation of Epstein--Barr virus (EBV)‐specific induced stem cell memory T (iT~SCM~) cells from human peripheral blood T cells. A,B, Generating EBV‐specific CD8^+^ iT~SCM~ cells from human peripheral blood T cells. EBV‐specific activated T cells mainly showed effector memory T (T~EM~) (CD8α^+^ carboxyfluorescein succinimidyl ester \[CFSE\]^low/−^ C‐C chemokine receptor type 7 \[CCR7\]^−^) cell phenotypes and central memory T (T~CM~) (CD8α^+^ CFSE ^low/−^ CCR7^+^) cell phenotypes (Day 0) (A). T~EM~ and T~CM~ cells were sorted, and then cocultured with OP9‐hDLL1 cells for 11 d. Flow cytometry analysis of CD8α^+^ cells 11 d after OP9‐hDLL1 cell coculture (B). C, Number of CD8α^+^ cells at 0, 3, 7, and 11 d after coculture with OP9‐hDLL1 cells. T~EM~ or T~CM~ cells (1 × 10^5^) were cocultured with OP9‐hDLL1 cells on Day 0. D, Recall responses to EBV. Flow cytometry analysis of CFSE dilution in each cell population (left). Column graph shows the fold increase of recovered T cells (n = 3 per group) (right). \**P* \< .05, \*\**P* \< .01 (one‐way ANOVA). Data are representative of independent experiments using human samples provided by three healthy donors. Error bars show SEM. CD45RA, CD45 isoform RA; FSC, forward scatter; SSC, side scatter; SSC‐H, side scatter‐height; SSC‐W, side scatter‐width](CAS-109-2130-g002){#cas13648-fig-0002}

3.2. T‐cell receptor stimulating procedures do not alter the efficiency of iT~SCM~ generation {#cas13648-sec-0007}
---------------------------------------------------------------------------------------------

For targeting tumor cells, antigen specificity is critical for adoptive T cell transfer. Expansion of endogenous antigen‐specific T cells is used in TIL therapy. Patients' peripheral T cells or tumor‐infiltrating T cells were expanded in vitro by culture with TAA‐loaded antigen‐presenting cells, tumor cells, or tumor tissues.[3](#cas13648-bib-0003){ref-type="ref"} Retroviral or lentiviral TCR or CAR transduction exogenously provides antigen specificity with pan‐TCR stimulation using anti‐CD3/CD28 beads.[26](#cas13648-bib-0026){ref-type="ref"} To compare the effects of TCR stimuli variations on iT~SCM~ generation, we stimulated peripheral CD8α^+^ T cells by LCL, CD3/CD28 beads, and melanoma antigen recognized by T cell‐1 (MART‐1) peptide‐pulsed monocyte‐derived dendritic cell (MART‐1 DC). These activated T cells were cocultured with OP9‐hDLL1 cells for 11 days following TCR stimulation (Figure [3](#cas13648-fig-0003){ref-type="fig"}A). The CD8α^+^ T cells activated by LCL and anti‐CD3/CD28 beads were expanded, and approximately 13.9% and 30.6% of activated cells showed T~CM~ phenotypes, respectively. Additionally, MART‐1 DC induced MART‐1‐specific T~CM~ cells (Figure [3](#cas13648-fig-0003){ref-type="fig"}B). We next isolated these cells and cocultured them with OP9‐hDLL1 cells. The induction step efficiently converted the T~CM~ cells into iT~SCM~ cells (Figure [3](#cas13648-fig-0003){ref-type="fig"}C), and the efficiency and amplification rates of iT~SCM~ from activated T~CM~ cells are summarized in Table [2](#cas13648-tbl-0002){ref-type="table"}. The iT~SCM~ cells from LCL and CD3/CD28 bead‐activated T cells were generated in greater number than from MART‐1‐specific T cells. These data indicate that activated T cells by any TCR stimulating procedure can be converted into iT~SCM~ cells.

![Generation of induced stem cell memory T (iT~SCM~) cells from antigen‐specific and CD3/CD28 bead‐activated T cells. A, Schematic for generating human iT~SCM~ cells from Epstein--Barr virus and melanoma antigen recognized by T cell‐1 (MART‐1)‐specific and CD3/CD28 bead‐activated T cells. B,C, Sorting panels of each CD8α^+^ central memory T (T~CM~) cell population stimulated by lymphoblastoid cell lines (LCL), MART‐1 peptide‐pulsed monocyte‐derived dendritic cells (MART‐1 DC), and CD3/CD28 beads. MART‐1^+^ T~CM~ cells were detected by MART‐1‐loaded MHC class I tetramer (B). CD45RA/C‐C chemokine receptor type 7 (CCR7) profiles of the CD8α^+^ T cells on Day 11 after coculture with OP9‐hDLL1 cells (C). Data are representative of independent experiments using human samples provided by two HLA‐A2^+^ healthy donors. CD45RA, CD45 isoform RA; CFSE, carboxyfluorescein succinimidyl ester; TCR, T‐cell receptor](CAS-109-2130-g003){#cas13648-fig-0003}

###### 

Percentages and number of recovered induced stem cell memory T (iT~SCM~) cells (mean ± SEM) after OP9‐hDLL1 coculture from activated T cells by various T‐cell receptor stimulation procedures

                   iT~SCM~ (%)    iT~SCM~ (×10^5^)
  ---------------- -------------- ------------------
  LCL              95.8 ± 0.36    5.44 ± 0.054
  MART‐1 DC        92.3 ± 0.36    0.52 ± 0.044
  CD3/CD28 beads   95.5 ± 0.071   3.86 ± 0.15

Lymphoblastoid cell line (LCL) and melanoma antigen recognized by T cell‐1 (MART‐1) peptide‐pulsed monocyte‐derived dendritic cell (DC), n* *= 3; CD3/CD28 beads, n = 6.

John Wiley & Sons, Ltd

3.3. Cytokine effects in the prime step on iT~SCM~ generation {#cas13648-sec-0008}
-------------------------------------------------------------

Interleukin‐15 and IL‐21 have been reported to enhance T~SCM~ inducing efficiency.[17](#cas13648-bib-0017){ref-type="ref"}, [21](#cas13648-bib-0021){ref-type="ref"} To investigate T cell stimulating and homeostatic cytokine effects in the prime step, we cocultured T cells with autologous LCL in the absence or presence of IL‐2, IL‐7, IL‐15, and IL‐21 (Figure [S1](#cas13648-sup-0001){ref-type="supplementary-material"}A). IL‐7 and IL‐15 made CD8α^+^ T cells highly proliferate compared with other conditions (Figure [S1](#cas13648-sup-0001){ref-type="supplementary-material"}B). Both T~EM~ and T~CM~ cells stimulated by IL‐2 and IL‐21 recovered comparable rates and counts of T~EM~ and T~CM~ cells that were activated in the absence of cytokines (Figure [S1](#cas13648-sup-0001){ref-type="supplementary-material"}C,D). CD45RA‐positive effector memory T (T~EMRA~) cells, which are CD45RA‐positive effector memory T cells, are thought of as terminally differentiated effector T cells. We also observed low numbers of T~SCM~ and T~EMRA~ cells in IL‐2‐, IL‐21‐, and cytokine‐absent conditions, whereas large numbers of T~SCM~ and T~EMRA~ cells stimulated by IL‐7 and IL‐15 were observed (Figure [S1](#cas13648-sup-0001){ref-type="supplementary-material"}C,D). We next cocultured IL‐7‐ and IL‐15‐stimulated T cells, which were individually isolated as T~SCM~, T~CM~, T~EM~, and T~EMRA~ phenotypes, with OP9‐hDLL1 cells (Figure [S1](#cas13648-sup-0001){ref-type="supplementary-material"}E). Both IL‐7‐ and IL‐15‐stimulated T~SCM~ cells completely retained T~SCM~ cell phenotypes and showed a 1‐ to 2‐fold increase in cell number after coculture with OP9‐hDLL1 cells (Figure [S1](#cas13648-sup-0001){ref-type="supplementary-material"}F, Table [3](#cas13648-tbl-0003){ref-type="table"}). T~CM~ cells activated in the absence of cytokines were efficiently converted into iT~SCM~ cells and recovered more than 10‐fold the number of cells compared with the number before OP9‐hDLL1 coculture, whereas a partial conversion into iT~SCM~ cells and 1‐ to 3‐fold increases in cell number compared with before the OP9‐hDLL1 coculture were observed in IL‐7 and IL‐15 stimulated T~CM~ cells from 1 × 10^5^ cells (Figure [S1](#cas13648-sup-0001){ref-type="supplementary-material"}F, Table [3](#cas13648-tbl-0003){ref-type="table"}). The absence of cytokines and the presence of IL‐7 and IL‐15 in the prime step could more efficiently convert into iT~SCM~ cells with a higher degree of proliferation than other T cells.

###### 

Percentages and number of recovered induced stem cell memory T (iT~SCM~) cells (mean ± SEM) after OP9‐hDLL1 coculture from activated T cells with or without cytokines in the prime step (n = 3 per group)

                     None              IL‐7             IL‐15
  ------------------ ----------------- ---------------- ----------------
  iT~SCM~ (%)                                           
  T~SCM~             NA                99.6 ± 0.033     99.6 ± 0.033
  T~CM~              89.20 ± 0.27      70.9 ± 0.290     39.6 ± 0.620
  T~EM~              4.39 ± 0.32       17.9 ± 0.300     17.0 ± 0.220
  T~EMRA~            NA                60.7 ± 0.660     55.3 ± 3.210
  iT~SCM~ (×10^5^)                                      
  T~SCM~             NA                2.76 ± 0.0110    0.830 ± 0.0260
  T~CM~              10.700 ± 0.4200   3.25 ± 0.1100    1.570 ± 0.0990
  T~EM~              0.019 ± 0.0011    0.070 ± 0.0041   0.042 ± 0.0036
  T~EMRA~            NA                0.43 ± 0.0370    0.260 ± 0.0360

IL, interleukin; NA, not applicable; T~CM~, central memory T; T~EM~, effector memory T; T~EMRA~, CD45RA‐positive effector memory T; T~SCM~, stem cell memory T.
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3.4. Conversion of long‐term cultured T cells into iT~SCM~ generation {#cas13648-sec-0009}
---------------------------------------------------------------------

In conventional T‐cell therapy, T cells are repeatedly stimulated for a long period to be expanded before infusion into patients; however, such long‐term TCR stimulation leads to T cell exhaustion or anergy.[27](#cas13648-bib-0027){ref-type="ref"} We assessed whether long‐term culture of T cells has any effects on iT~SCM~ generation. We first cocultured carboxyfluorescein succinimidyl ester (CFSE)‐labelled T cells with autologous LCL in the presence of IL‐7 or IL‐15. Seven days after the coculture, we isolated EBV‐specific T cells and then restimulated these cells by coculture with LCL for an additional 21 days (Figure [S2](#cas13648-sup-0002){ref-type="supplementary-material"}A,B). Long‐term culture strongly induced terminal differentiation of EBV‐specific T cells, whereas several T cells maintained T~SCM~ and T~CM~ phenotypes, as shown in Figure [S2](#cas13648-sup-0002){ref-type="supplementary-material"}(C). Cytokine‐depleted conditions did not allow T cells to survive for 2 weeks (data no shown). We next isolated each memory T cell subset and then cocultured them with OP9‐hDLL1 cells. Both IL‐7‐ and IL‐15‐stimulated T~SCM~ cells completely retained T~SCM~ cell phenotypes and showed a 0.8‐fold increase in cell counts after coculture with OP9‐hDLL1 cells (Figure [S2](#cas13648-sup-0002){ref-type="supplementary-material"}D, Table [4](#cas13648-tbl-0004){ref-type="table"}). Partial conversion into iT~SCM~ cells and 0.8‐fold increases in the number of cells were observed in IL‐7‐stimulated T~CM~ cells and IL‐7‐ or IL‐15‐stimulated T~EMRA~ cells (Figure [S2](#cas13648-sup-0002){ref-type="supplementary-material"}D, Table [4](#cas13648-tbl-0004){ref-type="table"}). Small percentage of interleukin‐15‐stimulated T~CM~ cells and T~EM~ cells were converted into iT~SCM~ cells (Figure [S2](#cas13648-sup-0002){ref-type="supplementary-material"}D, Table [4](#cas13648-tbl-0004){ref-type="table"}). These data indicate that the presence of IL‐7 in long‐term priming could efficiently generate iT~SCM~ cells from T~SCM~, T~CM~, and T~EMRA~ cells.

###### 

Percentages and cell count of recovered induced stem cell memory T (iT~SCM~) cells (mean ± SEM) after OP9‐hDLL1 coculture from long‐term activated T cells (n = 3 per group)

                     IL‐7             IL‐15
  ------------------ ---------------- ------------------
  iT~SCM~ (%)                         
  T~SCM~             99.40 ± 0.133    98.90 ± 0.34
  T~CM~              58.50 ± 3.920    0.27 ± 0.059
  T~EM~              0.62 ± 0.110     0.63 ± 0.11
  T~EMRA~            29.40 ± 0.150    47.40 ± 2.01
  iT~SCM~ (×10^5^)                    
  T~SCM~             0.830 ± 0.0440   0.7900 ± 0.00760
  T~CM~              0.840 ± 0.0640   0.0097 ± 0.00220
  T~EM~              0.006 ± 0.0010   0.0020 ± 0.00044
  T~EMRA~            0.140 ± 0.0063   0.0900 ± 0.00370

IL, interleukin; T~CM~, central memory T; T~EM~, effector memory T; T~EMRA~, CD45RA‐positive effector memory T; T~SCM~, stem cell memory T.
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3.5. Cytokine effects in the induction step on iT~SCM~ generation {#cas13648-sec-0010}
-----------------------------------------------------------------

To assess cytokine effects in the induction step, we next cocultured T cells with autologous LCL for 7 days, and EBV‐specific T cells were then transferred onto OP9‐hDLL1 layers for 11 days in the presence of IL‐2, IL‐7, IL‐15, and IL‐21 (Figure [4](#cas13648-fig-0004){ref-type="fig"}A). The absence of cytokines induced T cell death in the induction step (data not shown). The conversion efficiency rates of iT~SCM~ cells were 8% (IL‐2), 84% (IL‐7), 44% (IL‐15), and 21% (IL‐21) (Figure [4](#cas13648-fig-0004){ref-type="fig"}B,C). Although IL‐7 and IL‐15 generated a greater number of iT~SCM~ cells than the initial cell number on Day 0, fewer IL‐2‐ and IL‐21‐induced iT~SCM~ cells were recovered than the initial cell count (Figure [4](#cas13648-fig-0004){ref-type="fig"}D). These results indicate that both IL‐7 and IL‐15 generate a high number of iT~SCM~ cells in the induction step, but IL‐7 generates iT~SCM~ cells with high purity and certain cell expansion, whereas IL‐15 generates a larger number of iT~SCM~ cells with lower purity than IL‐7 does. Next, to validate synergistic effects of cytokines, we induced iT~SCM~ cells in the presence of IL‐7 with or without IL‐2, IL‐15, and IL‐21. The combination of IL‐7 and IL‐15 effectively converted into iT~SCM~ cells and a larger number of the cells were recovered by the combination, compared with other conditions (Figure [S3](#cas13648-sup-0003){ref-type="supplementary-material"}).

![Effects of cytokines in the induction step for induced stem cell memory T (iT~SCM~) cell generation. A, Schematic for the induction of human iT~SCM~ cells by human interleukin (IL)‐2, IL‐7, IL‐15, and IL‐21. Coculture with OP9‐hDLL1 layers was undertaken in the presence of human IL‐2 (20 ng/mL), human IL‐7 (10 ng/mL), human IL‐15 (20 ng/mL), or human IL‐21 (20 ng/mL). B, Flow cytometry analysis of CD8α^+^ T cells after OP9‐hDLL1 cell coculture with multiple cytokines. C,D, Percentages (C) and cell counts (D) of recovered iT~SCM~ cells after OP9‐hDLL1 coculture (n = 3 per group). \*\**P* \< .01 (one‐way ANOVA). Data are representative of at least two independent experiments. Error bars show SEM](CAS-109-2130-g004){#cas13648-fig-0004}

3.6. Characterization of iT~SCM~ populations generated by different priming methods {#cas13648-sec-0011}
-----------------------------------------------------------------------------------

It has been shown that the transcriptional program strictly controls effector and memory T cell fate and functions. Blimp‐1 (encoded by *PRDM1*) and T‐bet (encoded by *TBX21*) positively regulated terminal differentiation, whereas Eomes and B‐cell lymphoma 6 protein (Bcl‐6) promote memory formation and retain memory homeostasis.[28](#cas13648-bib-0028){ref-type="ref"} These transcriptional programs govern not only effector/memory formation but also T cell survival and proliferative and effector ability.

To characterize iT~SCM~ cells derived from CD3/CD28 bead‐activated T cells (beads‐iT~SCM~) and those cells derived from LCL‐activated T cells (LCL‐iT~SCM~), we assessed these gene profiles and proliferative ability. Blimp‐1 and T‐bet were poorly expressed in all iT~SCM~ populations compared with T~EM~ and T~CM~ cells (Figure [5](#cas13648-fig-0005){ref-type="fig"}A,B). High expression of *EOMES* and low expression of *BCL6* were observed in beads‐iT~SCM~ cells, whereas the opposite results were observed in LCL‐iT~SCM~ cells either induced in the presence of IL‐7 (designated as "iT~SCM~ (IL‐7)") or IL‐15 (designated as "iT~SCM~ (IL‐15)") (Figure [5](#cas13648-fig-0005){ref-type="fig"}A,B). Beads‐iT~SCM~ and iT~SCM~ (IL‐7) cells showed strong proliferative ability after recall response, but weak proliferation was observed in iT~SCM~ (IL‐15) cells (Figure [5](#cas13648-fig-0005){ref-type="fig"}C,D). Proliferation of iT~SCM~ (IL‐7) cells was higher than beads‐iT~SCM~ cells (Figure [5](#cas13648-fig-0005){ref-type="fig"}C,D). These results indicate that effector‐associated programs are suppressed in all iT~SCM~ populations and iT~SCM~ (IL‐7) cells have superior proliferative ability compared to other iT~SCM~ cells.

![Gene profile and proliferative ability of induced stem cell memory T (iT~SCM~) cells. A,B, Gene expression in bead‐generated effector memory T (T~EM~), central memory T (T~CM~), and iT~SCM~ cells, and lymphoblastoid cell line‐generated T~EM~,T~CM~, and iT~SCM~ cells induced by interleukin (IL)‐7 (iT~SCM~ (IL‐7)) or IL‐15 (iT~SCM~ (IL‐15)) (n = 3 per group). Each gene expression was normalized by 18S rRNA expression level. C,D, Recall responses by T‐cell receptor stimulation. Each T cell population (5 × 10^4^) was activated by CD3/CD28 beads for 60 h. Column graphs show the fold increase of recovered T cells (n = 3 per group). \*\**P* \< .01 (one‐way ANOVA). Data are representative of at least two independent experiments. Error bars show SEM](CAS-109-2130-g005){#cas13648-fig-0005}

We then tried to generate TAA‐specific iT~SCM~ cells. In Figure [3](#cas13648-fig-0003){ref-type="fig"}, MART‐1‐specific iT~SCM~ cells could be converted from MART‐1‐specific T~CM~ cells, but the recovered cell number was much lower than LCL‐ and beads‐iT~SCM~ cells. To overcome this low yield, we optimized culture conditions for generating MART‐1‐specific iT~SCM~ cells. We first isolated naïve T cells from PBMC (endogenous T~SCM~ cells were depleted by anti‐CD95 antibody) and cocultured with autologous MART‐1 DCs for 7 days (Figure [6](#cas13648-fig-0006){ref-type="fig"}A,B). Next, we purified MART‐1 tetramer^+^ T cells and restimulated them using CD3/CD28 beads for additional 7 days (Figure [6](#cas13648-fig-0006){ref-type="fig"}C). Fourteen days after stimulation, most of the activated MART‐1‐specific T cells, which showed T~EM~ phenotypes, were transferred onto an OP9‐hDLL1 layer in the presence of IL‐7 alone or IL‐7 and IL‐15 (Figure [6](#cas13648-fig-0006){ref-type="fig"}D). The combination of IL‐7 and IL‐15 could effectively induce LCL‐iT~SCM~ cells with more than 80‐fold expansion (Figure [S3](#cas13648-sup-0003){ref-type="supplementary-material"}). The combination could effectively induce MART‐1‐specific iT~SCM~ cells regardless of donors; IL‐7 alone could not effectively induce iT~SCM~ cells from one donor (Figure [6](#cas13648-fig-0006){ref-type="fig"}E, Table [5](#cas13648-tbl-0005){ref-type="table"}). Gene profiles of the iT~SCM~ cells resembled those of LCL‐iT~SCM~ cells and showed strong proliferative ability compared with the cells before iT~SCM~ induction (Figure [6](#cas13648-fig-0006){ref-type="fig"}F,G). These results confirm that this two‐step iT~SCM~ induction system can be applied regardless of activation methods.

![A, Schematic for generating human induced stem cell memory T (iT~SCM~) cells from melanoma antigen recognized by T cell‐1 (MART‐1)‐specific activated T cells. Purified naïve CD8α^+^ T cells were activated by MART‐1 peptide‐pulsed monocyte‐derived dendritic cells (MART‐1 DC) for 7 d. MART‐1‐specific T cells were then purified and restimulated by CD3/CD28 beads for 7 d. After 14 d of stimulation, whole MART‐1‐specific T cells were cocultured with OP9‐hDLL1 cells for 11 d in the presence of interleukin (IL)‐7 or both IL‐7 and IL‐15. B‐E, Sorting panels of each step of CD8α^+^ T cell populations. Naïve T cells were purified from HLA‐A2^+^ PBMCs by cell sorting, gated as CD8α^+^ CD95^−^ CD45RA ^+^ C‐C chemokine receptor type 7 (CCR7)^+^ cells (B). MART‐1^+^ central memory T (T~CM~) cells were detected by MART‐1‐loaded MHC class I tetramer (C). CD45RA/CCR7 profiles of the CD8α^+^ T cells on Day 0 before coculture with OP9‐hDLL1 cells (D) and on Day 11 after coculture with OP9‐hDLL1 cells (E). F, Gene expression in MART‐1‐specific T cells before (Day 0) or after (Day 11) OP9‐hDLL1 coculture. G, Recall responses by T‐cell receptor stimulation. MART‐1‐specific activated (Day 0) and iT~SCM~ cells (Day11) (5 × 10^4^) were activated by CD3/CD28 beads for 60 h. Column graphs show the fold increase of recovered T cells (n = 3 per group). \**P* \< .05, \*\**P* \< .01 (Student\'s *t*‐test). Data are representative of independent experiments using human samples provided by two HLA‐A2^+^ healthy donors. Error bars show SEM. CD45RA, CD45 isoform RA; FSC, forward scatter; HS, healthy subject; SSC, side scatter; SSC‐H, side scatter‐height; SSC‐W, side scatter‐width](CAS-109-2130-g006){#cas13648-fig-0006}

###### 

Percentages and cell count of recovered induced stem cell memory T (iT~SCM~) cells (mean ± SEM) after OP9‐hDLL1 coculture from melanoma antigen recognized by T cell‐1‐specific T cells (n* *=* *3 per group)

                     HS1               HS2
  ------------------ ----------------- --------------
  iT~SCM~ (%)                          
  IL‐7               13.4 ± 0.42       68.1 ± 0.44
  IL‐7 + IL‐15       76.4 ± 0.71       79.7 ± 0.26
  iT~SCM~ (×10^5^)                     
  IL‐7               0.004 ± 0.00058   1.16 ± 0.087
  IL‐7 + IL‐15       2.250 ± 0.03900   11.9 ± 0.860

HS, healthy subject; IL, interleukin.

John Wiley & Sons, Ltd

3.7. Application of human iT~SCM~ cells for cancer immunotherapy {#cas13648-sec-0012}
----------------------------------------------------------------

The iT~SCM~ cells showed strong proliferation following recall response and long‐term persistence after adoptive transfer.[29](#cas13648-bib-0029){ref-type="ref"} Thus, we investigated the antitumor effects of human iT~SCM~ cells using human LCL‐bearing mice. We s.c. inoculated LCL into NOD.Cg‐*PrkDC* ^*cid*^ *Il2rg* ^*tm1Wjl*^ (NSG) mice. Eight days after tumor inoculation, we transferred EBV‐specific T~EM~, T~CM~, and iT~SCM~ cells into autologous LCL‐bearing mice (Figure [7](#cas13648-fig-0007){ref-type="fig"}A). As shown in Figure [7](#cas13648-fig-0007){ref-type="fig"}(B), EBV‐specific iT~SCM~ cells showed significantly stronger suppressive effects on LCL growth than EBV‐specific T~EM~ and T~CM~ cells. Consequently, EBV‐specific iT~SCM~ cells improved the survival rates of the mice (Figure [7](#cas13648-fig-0007){ref-type="fig"}C). Tumor antigen‐specific human iT~SCM~ cells are more likely to have potent antitumor effects and are appropriate for adoptive cancer immunotherapy.

![Antitumor potential of human induced stem cell memory T (iT~SCM~) cells. A, Schematic for generating a humanized tumor model mice for adoptive T‐cell therapy. Severe immunodeficient (NOD.Cg‐*PrkDC* ^*cid*^ *Il2rg* ^*tm1Wjl*^ */Szj*,NSG) mice were s.c. inoculated with 5 × 10^6^ Epstein--Barr virus‐transformed lymphoblastoid cell line (LCL). Effector memory T (T~EM~), central memory T (T~CM~), and iT~SCM~ cells (5 × 10^5^) were adoptively transferred into LCL‐bearing mice 12 d after LCL inoculation. B, Tumor volumes of LCL‐bearing mice. C, Survival rates of LCL‐bearing mice (no transfer and T~EM~, n = 7; T~CM~, n = 4; iT~SCM~, n = 6) \*\**P* \< .01 (one‐way ANOVA \[B\]; Long‐rank test \[C\]). Data are representative of at least two independent experiments. Error bars show SEM](CAS-109-2130-g007){#cas13648-fig-0007}

4. DISCUSSION {#cas13648-sec-0013}
=============

Stem cell memory T cells have functional advantages for adoptive T‐cell therapy compared with other memory T cell populations.[11](#cas13648-bib-0011){ref-type="ref"} Thus, T~SCM~ cells should play a significant role in cancer immunotherapy. We previously reported a novel T~SCM~ generating method, converting memory and effector T cell subsets into T~SCM~ cells. In this report, we optimized the conditions for generating iT~SCM~ cells for potential adoptive immunotherapy. Our method constitutes two steps, the prime step and the induction step. This method can induce iT~SCM~ cells regardless of the priming method: from activated T cells by non‐specific TCR stimulation (CD3/CD28 beads), expanded T cells from existing memory T cells with a specific antigen (EBV), or expanded antigen‐specific T~EM~ cells from naive T cells (MART‐1). As T cells expand during both priming and induction steps, we achieved a high iT~SCM~ cell yield. In our experiments, more than 1 × 10^6^ MART‐1‐specific iT~SCM~ cells were recovered from 100 mL whole blood. In addition, we showed the conceptual advantage of human tumor antigen‐specific iT~SCM~ cells for antitumor adoptive T‐cell therapy.

Efficiency and expansion of antigen‐specific iT~SCM~ cells are highly dependent on cytokines. For the induction of EBV‐specific iT~SCM~ cells, IL‐7 was sufficient to generate a large number of EBV‐specific iT~SCM~ cells (Figures [4](#cas13648-fig-0004){ref-type="fig"},[S1](#cas13648-sup-0001){ref-type="supplementary-material"}). Combined stimulation with IL‐7 and IL‐15 efficiently induced MART‐1‐specific iT~SCM~ cells from MART‐1‐specific T~EM~ cells during the induction step (Figure [6](#cas13648-fig-0006){ref-type="fig"}). The cultural settings provided high yield (15‐fold) of the iT~SCM~ cells compared with only IL‐7 stimulation (Table [5](#cas13648-tbl-0005){ref-type="table"}). The reason why different cytokines are required for LCL‐induced iT~SCM~ cells and MART‐1 DC‐induced iT~SCM~ cells is not clear at present. This may be because of the difference in antigen‐presenting cells (B cells vs DCs) or the difference in the origin of primed T cell phenotypes (in vivo memory T cells in LCL‐iT~SCM~ and naïve T cells in MART‐1 iT~SCM~).

Expression of key transcription factors for memory subset differentiation and functions was compared in iT~SCM~ cells induced from different sources (Figures [5](#cas13648-fig-0005){ref-type="fig"}, [6](#cas13648-fig-0006){ref-type="fig"}). Blimp‐1 and T‐bet, which positively regulate terminal effector formation were low in three different types of iT~SCM~ cells. Although Eomes and Bcl‐6 mRNA expression appear to be variable in iT~SCM~ cells induced from CD3/CD28 bead‐activated T cells, reduced expression of *EOMES* and increased expression of *BCL6* were observed in both MART‐1 DC‐induced iT~SCM~ cells and LCL‐induced iT~SCM~ cells, suggesting that iT~SCM~ phenotypes are mostly conserved, regardless of the priming method.

One could argue that iT~SCM~ cells might be a result of selective expansion of pre‐existing T~SCM~‐like cells. However, we generated MART‐1‐specific iT~SCM~ cells from naïve T cells that excluded T~EMRA~, T~EM~, T~CM~, and T~SCM~ cells, from healthy donors. Thus, the possibility of expanding pre‐existing T~SCM~ cells is unlikely, although it is very difficult to completely exclude this possibility of contamination. In addition, it is hard to show a direct generation of iT~SCM~ cells from pre‐existing T~EM~ cells and T~CM~ cells in vivo. We showed that iT~SCM~ cells can be generated from activated T cells from immunized mice, which include T~EM~ cells. However, it is difficult to show the direct conversion of human existing T~EM~ cells to iT~SCM~ cells from healthy donors without immunization. Nevertheless, it is a great advantage of our method for immunotherapy that iT~SCM~ cells can be generated from T~EM~ and T~CM~ cells primed from any type of T cell, regardless of naive or memory.

The functional role of Notch signaling in iT~SCM~ cells remains to be clarified. Previously, we showed that iT~SCM~ cells can be induced by coculture with OP9‐DL1 but not with OP9 cells. In addition, Notch signaling inhibitors strongly suppressed generation of iT~SCM~ cells.[12](#cas13648-bib-0012){ref-type="ref"} These data indicate that Notch signals are indispensable for the induction of iT~SCM~ cells. Previous work by Maekawa et al[30](#cas13648-bib-0030){ref-type="ref"} also reported that Notch signaling plays a central role in maintaining CD4^+^ memory T cells. Therefore, we think that Notch signaling is important not only for induction but also for maintenance of iT~SCM~ cells.

As a next step for cancer immunotherapy, establishing the method to generate iT~SCM~ cells from exhausted T cells within the tumor. As we could not obtain TILs from patients at present, we have not addressed the question whether iT~SCM~ cells can be generated directly from TILs. However, as TILs can be expanded in vitro by IL‐2 or TCR stimulation, we speculate that iT~SCM~ cells will be induced from TILs after expansion by our methods, like LCL‐activated T cells or MART‐1 DC‐activated T cells. We also need to improve the method as the good manufacturing practice‐graded methods without the use of OP9‐hDLL1 feeder cells and stimulator LCLs.
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